MedTrace Logo

A Study to Evaluate the Efficacy and Safety of AD-223

NCT06052748 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 502

Last updated 2025-04-04

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of AD-223

Conditions

  • Hypertension,Essential

Interventions

DRUG

AD-223A

PO, Once daily(QD), 8weeks

DRUG

AD-223B

PO, Once daily(QD), 8weeks

DRUG

AD-223C

PO, Once daily(QD), 8weeks

DRUG

AD-223A Placebo

PO, Once daily(QD), 8weeks

DRUG

AD-223B Placebo

PO, Once daily(QD), 8weeks

DRUG

AD-223C Placebo

PO, Once daily(QD), 8weeks

Sponsors & Collaborators

  • Addpharma Inc.

    lead INDUSTRY

Principal Investigators

  • Jin Ho Shin, M.D., Ph.D · Hanyang University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-15
Primary Completion
2025-03-27
Completion
2025-04-02

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06052748 on ClinicalTrials.gov